

# References

## Chapter 7

- 1 Lassen A, Hallas J, Schaffalitzky De Muckadell OB. Use of anti-secretory medication: a population-based cohort study. *Alimentary Pharmacology & Therapeutics*. 2004;**20**(5):577–83.
- 2 WHO Collaborating Centre for Drug Statistics Methodology website: [www.whocc.no](http://www.whocc.no).
- 3 MedStat website: [www.medstat.dk](http://www.medstat.dk).
- 4 Van Staa TP, Abenham L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharmacoepidemiologic studies. *Journal of Clinical Epidemiology*. 1994;**47**(2):183–9.
- 5 Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. *European Journal of Clinical Pharmacology*. 1997;**53**(1):7–11.
- 6 Pottegård A, Zoëga H, Hallas J, Damkier P. Use of SSRIs among Danish children: a nationwide study. *European Child and Adolescent Psychiatry*. 2014;**23**(12):1211–18.
- 7 Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. *Journal of Clinical Epidemiology*. 2010;**63**(4):422–7.
- 8 Nielsen LH, Løkkegaard E, Andreasen AH, Keiding N. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. *Pharmacoepidemiology and Drug Safety*. 2008;**17**(4):384–8.
- 9 Suissa S. Immortal time bias in pharmacoepidemiology. *American Journal of Epidemiology*. 2008;**167**(4):492–9.
- 10 Pottegård A, Hallas J. Assigning exposure duration to single prescriptions by use of the waiting time distribution. *Pharmacoepidemiology and Drug Safety*. 2013;**22**(8):803–9.
- 11 Hallas J, Støvring H. Templates for analysis of individual-level prescription data. *Basic Clinical Pharmacology and Toxicology*. 2006;**98**(3):260–5.
- 12 Gardarsdottir H, Heerdink ER, Egberts ACG. Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands. *Pharmacoepidemiology and Drug Safety*. 2006;**15**(5):338–43.
- 13 Rothman KJ. *Epidemiology: An Introduction*. Oxford, Oxford University Press, 2002.
- 14 Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. *Am J Med*. 2009; 122: 961.e7–13.
- 15 Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *Journal of the American Medical Association*. 2002;**288**(4):455–61.
- 16 Østergaard K, Hallas J, Bak S, Christensen Rd, Gaist D. Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data. *European Journal of Clinical Pharmacology*. 2012;**68**(12):1631–7.
- 17 Alho JM. On prevalence, incidence, and duration in general stable populations. *Biometrics*. 1992;**48**(2):587–92.
- 18 Suissa S, Spitzer WO, Abenham L, Downey W, Gardiner RJ, Fitzgerald D. Risk of death from human insulin. *Pharmacoepidemiology and Drug Safety*. 1992;**1**:169–75.
- 19 Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *New England Journal of Medicine*. 1998;**339**(4):229–34.

- 20** Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. *Lancet*. 2003;**362**(9383):537–8.
- 21** Nielsen LH, Løkkegaard E, Andreasen AH, Hundrup YA, Keiding N. Estimating the effect of current, previous and never use of drugs in studies based on prescription registries. *Pharmacoepidemiology and Drug Safety*. 2009;**18**(2):147–53.
- 22** Rosholm JU, Gram LF, Isacson G, Hallas J, Bergman U. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. *European Journal of Clinical Pharmacology*. 1997;**52**(3):205–9.
- 23** Brostrøm S, Hallas J. Persistence of antimuscarinic drug use. *European Journal of Clinical Pharmacology*. 2009;**65**(3):309–14.
- 24** Pottegård A, Poulsen BK, Larsen MD, Hallas J. Dynamics of vitamin K-antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. *Journal of Thrombosis and Haemostasis*. 2014;**12**(9):1413–18.
- 25** Arnlind MH, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson EW. Regional variation and adherence to guidelines for drug treatment of asthma. *European Journal of Clinical Pharmacology*. 2010;**66**(2):187–98.
- 26** Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. *Epidemiology*. 1997;**8**:666–70.
- 27** Støvring H, Vach W. Estimation of prevalence and incidence based on occurrence of health-related events. *Statistics in Medicine*. 2005;**24**(20):3139–54.
- 28** Støvring H. Selection bias due to immigration in pharmacoepidemiologic studies. *Pharmacoepidemiology and Drug Safety*. 2007;**16**(6):681–6.
- 29** Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Counting drugs to understand the disease: the case of measuring the diabetes epidemic. *Population Health Metrics*. 2007;**5**:2.
- 30** Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. *European Journal of Clinical Pharmacology*. 1996;**50**(3):161–5.
- 31** Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clinical Pharmacology and Toxicology*. 2010;**106**(2):86–94.
- 32** World Health Organization. Introduction to drug utilization research. Oslo, World Health Organization, 2003.
- 33** Pottegård A, Bjerregaard BK, Larsen MD, Larsen KS, Hallas J, Knop FK, et al. Use of exenatide and liraglutide in Denmark: a drug utilization study. *European Journal of Clinical Pharmacology*. 2014;**70**(2):205–14.
- 34** Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI. The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. *European Journal of Clinical Pharmacology*. 2013;**69**(3):589–98.
- 35** Hennessy S, Freeman CP, Cunningham F. US Government Claims Databases. In: Strom BL, Kimmel SE, eds. *Pharmacoepidemiology*, 5th edn. Chichester, John Wiley & Sons, 2012.
- 36** Pottegård A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. *European Journal of Clinical Pharmacology*. 2012;**68**(10):1443–50.